[
    "{\"step_by_step_thinking\": \"Document [0] states that sotatercept resulted in a significantly greater reduction from baseline in pulmonary vascular resistance than placebo in participants with pulmonary arterial hypertension. Document [1] also mentions that treatment with sotatercept resulted in a reduction in pulmonary vascular resistance in patients receiving background therapy for pulmonary arterial hypertension. Document [8] also supports this by stating that sotatercept reduced the PVR and improved exercise tolerance. Therefore, it can be concluded that Sotatercept is effective for Pulmonary Arterial Hypertension.\", \"answer_choice\": \"A\"}"
]